# Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients

> **NCT03618602** · PHASE1 · UNKNOWN · sponsor: **Shanghai Theorion Pharmaceutical Co Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Refractory Multiple Myeloma
- Recurrent Multiple Myeloma

## Interventions

- **DRUG:** Bisthianostat

## Key facts

- **NCT ID:** NCT03618602
- **Lead sponsor:** Shanghai Theorion Pharmaceutical Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-25
- **Primary completion:** 2020-04
- **Final completion:** 2020-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618602, "Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03618602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*